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Elevated serum levels of uric acid consistently correlate with
hypertension, but the directionality of the association
remains debated. To help define this relationship, we used a
controlled setting within a homogeneous Amish community
and the Mendelian randomization of a nonsynonymous
coding single-nucleotide polymorphism, rs16890979
(Val253Ile), in the SLC2A9 gene. This gene expresses the
GLUT9 transporter that also transports uric acid and is
associated with lower serum uric acid levels. We studied the
unconfounded association between genotype and blood
pressure in 516 Amish adults, each placed for 6 days on
standardized diets, first with high sodium, followed by low
sodium, with an intervening washout period. Blood pressure,
measured using 24-h ambulatory monitoring, during
both diet periods was used as the primary outcome. All
participants were free of diuretic or other antihypertensive
medications and the relationships between GLUT9 genotype
and both serum uric acid and blood pressure were assessed.
Each copy of the GLUT9 minor Ile allele was found to confer a
significant 0.44mg/dl reduction in serum uric acid and was
associated with a significant mean decrease in the systolic
blood pressure of 2.2 and 1.5mmHg on the high- and low-
sodium diet, respectively. Thus, a Mendelian randomization
analysis using variants in the GLUT9 gene indicates that a
decrease in serum uric acid has a causal effect of lowering
blood pressure.
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An association between serum uric acid (UA) and blood
pressure (BP) has long been established; over 40 years have
passed since the observation that 425% of untreated
hypertensive patients were hyperuricemic.1 Numerous
large-scale observational studies have shown persistent
independent associations between serum UA and BP, as well
as with various other cardiovascular (CV) outcomes.2–4
However, the complex interplay among metabolic syndrome
components, as well as renal function, has produced strong
debate about the causality and directionality of the observed
associations. Indeed, although UA initially gained much
attention as an important mediator of vascular disease, it
subsequently was felt to be a secondary marker of disease and
was dropped from standard metabolic panels. More recently,
there has been resurgence in the interest of the likely causal
association between serum UA and a variety of CV-related
outcomes, most notably hypertension. For example, both
animal and human studies have shown that the presence of
hyperuricemia precedes the development of hypertension and
that, after adjusting for multiple independent risk factors,
hyperuricemia carries an increased relative risk of developing
hypertension.3,5–7 However, these studies, although often
providing compelling arguments, are not sufficient to fully
resolve concerns regarding the temporality of UA change
along with more subtle potential confounders and BP. There
have also been some small trials showing an improvement in
BP, C-reactive protein, and renal function in response to
treatment with allopurinol.8,9 However, it remains unclear
whether these benefits were related to the ability of
allopurinol to inhibit xanthine oxidase and/or lower
serum UA.
Although diet is well known to modulate serum UA
concentration, genetic variability is also significantly asso-
ciated with serum UA levels. The gene most strongly
associated with UA levels resides on chromosome 4 and
codes for GLUT9 (also known as SLC2A9), a recently
discovered key urate transporter. Genetic variants of GLUT9
have been strongly associated with reduced levels of serum
UA in several Caucasian cohorts, including ours,10–16 and
in non-Caucasian cohorts.17–19 Specifically, in our cohort,
out of a total of 102 genotyped single-nucleotide poly-
morphisms (SNPs), a missense variant that codes for a Val to
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Ile amino-acid substitution at position 253 on the GLUT9
gene (GLUT9 Val253Ile) was most significantly associated
with a reduction in UA concentration of B0.5 mg/dl in
women and B0.25 mg/dl in men per copy,12 and is
associated with increased renal clearance of UA.13,20
The discovery of the aforementioned GLUT9 Val253Ile
variant allows for an opportunity to study whether UA levels
are, in fact, causal of changes in BP, by using a method known
as Mendelian randomization. The Mendelian randomization
principle relies on the tenet that alleles, and hence genotypes,
are randomly assigned during gamete formation. The main
advantage of this method is that gamete formation occurs
before birth and is therefore unaffected by traditional
confounders that occur after conception, such as diet,
socioeconomic status, access to health care, and all other
environmental factors. Because relationships between geno-
types and outcomes have only limited susceptibility to
confounding and are not subject to reverse causality, genetic
variation may be used to establish directionality and infer
causality between a certain gene product and a specific
outcome. Therefore, Mendelian randomization is akin to
a randomized trial design with genetic variation used as a
proxy for an exposure that leads to a given outcome. In
a theoretical randomized trial design, inheritance of the
GLUT9 Ile allele would be analogous to randomly being
assigned probenecid, a uricosuric agent, from birth, whereas
inheritance of the wild-type genotype would be analogous to
receiving placebo. In this paper, we set out to determine
whether exposure to a genotype-associated lowering in serum
UA concentration, while on standardized prepared high- and
low-salt diets, and free of any diuretic or other antihyperten-




The 868 participants of the HAPI (Hereditary and Phenotype
Intervention) Heart Study ranged in age from 20 to 80 years
at the time of the study, and 53% were men. Table 1 gives the
baseline clinical characteristics of the sample.
Association of the GLUT9 Val253Ile genotype with serum UA
level
We previously performed a genome-wide association study of
serum UA and found SNPs within the GLUT9 gene to be
most strongly associated with serum UA.12 Included in the
genome-wide association study were 98 GLUT9 variants.
However, as these SNPs were not viewed as functional, we
then identified four nonsynonymous SNPs within GLUT9
and genotyped those to see whether a putative SNP could be
identified. Of these, a missense SNP rs16890979 (Val245Ile)
in exon 8 proved to be the best associated marker and the
only independently associated one, when included with the
other SNPs in the same regression model.12 On the basis of
these findings, we selected this variant for our Mendelian
randomization analysis. No deviation from Hardy–Weinberg
equilibrium was noted. The GLUT9 Val253Ile genotype was
strongly associated with serum UA levels (Table 2), and
accounted for 4.3% of the variance in our population.
Among homozygotes for the Ile allele (Ile/Ile), serum UA
levels were nearly 1 mg/dl lower than for those with the wild-
type (Val/Val) genotype; each copy of the Ile allele conferred
an B0.45 mg/dl reduction in UA (P¼ 3.2 1011). Con-
sistent with previous reports,11,12,16,21,22 this effect was more
pronounced in women than in men (data not shown). This
strong association between genotype and phenotype is
consistent with previous evidence and supports the first
condition for the use of Mendelian randomization, as a weak
genotype effect would otherwise yield low power to detect
any effect.
Association of serum UA levels with BP
Consistent with previous studies, we found serum UA levels
to be correlated with multiple measurements of BP, metabolic
syndrome factors, and renal function. Both our BP and
serum UA measurements were approximately normally
distributed and did not require normalization. Regression
coefficients and P-values from this analysis are shown in
Table 2. After standardized BP was taken on the initial clinic
visit, subjects began 6 days of a high-salt diet, followed by an
8- to 14-day washout period, and then 6 days of a low-salt
diet. Serum UA levels were positively correlated with multiple
measurements of baseline BP (taken during clinic visit one
and a home visit following the washout period) and 24-h
ambulatory BP measurements. However, it is important to
remember that these associations may not represent valid
estimates of true causal effects given that they are subject to
both confounding and reverse causality.
Association of the GLUT9 Val253Ile genotype with BP
Mean values and regression coefficients of baseline and 24-h
BP measurements by genotype are presented in Table 2. The
right-most column of Table 2 shows the two-stage estimate of
Table 1 | Clinical characteristics (mean (s.d.)) of the 868 Old
Order Amish enrolled in the HAPI Heart Study, Lancaster
County, Pennsylvania
Characteristic Men (n=460) Women (n=408)
Age (years) 42.2 (13.6) 45.4 (14.2)
BMI (kg/m2) 25.6 (3.2) 27.8 (5.5)
Total cholesterol (mg/dl) 202.5 (44.3) 215.7 (49.0)
Triglycerides (mg/dl) 63.9 (1.7) 73.8 (45.4)
SBP (mmHg) 121.5 (12.6) 121.4 (16.9)
DBP (mmHg) 77.6 (8.8) 75.8 (8.4)
Diabetes (%) 0.9 1.0
Current smokers (%)a 20.0 0.0
Lipid-lowering meds (%)b 1.0 1.0
Antihypertensive meds (%)b 0.2 0.3
Abbreviations: BMI, body mass index; DBP, diastolic blood pressure; HAPI, Hereditary
and Phenotype Intervention; meds, medication; SBP, systolic blood pressure.
aIndicates use of cigarettes, cigars, and pipes.
bMedication use assessed at the time of recruitment, before participants were asked
to discontinue use, per our study protocol.
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the serum UA–BP association derived from the Mendelian
randomization approach that uses the GLUT9 Val253Ile
genotype. It is important to note that our clinic visit one BP
measurements (average of three repeated BP measurements
at a single visit) were obtained when the individuals were on
a liberal diet, and these were not associated with genotype
under an additive model (Table 2). However, when the same
participants were on standardized prepared high-salt diets
(delivered to the home of each subject), we noted a
significant additive genotype-mediated association with our
24-h mean BP measurements. Moreover, this was internally
replicated when the same individuals were on standardized
low-salt diets where each Ile allele was associated with a
decrease in BP. Our genotype-mediated effect estimate went
from null effect (0.08 mm Hg) per Ile allele on liberal diet
to 1.5 mm Hg on low-salt diet and 2.2 mm Hg on high-
salt diet (Table 2). Our power is over 90% to identify the
observed effect with our given sample size. The potentially
confounded associations between serum UA and renal
function, body mass index, triglycerides, and glucose were
nullified under the genotype-based approach (Table 2).
Association of serum UA with salt sensitivity
As with BP readings, mean values and regression coefficients
of measurements of salt sensitivity are also presented in
Table 2. Genotype was not associated with salt sensitivity,
defined as BP on high-salt diet minus BP on low-salt diet
(P¼ 0.446). It should be noted that our relatively healthy and
young Caucasian population were mostly non-salt sensitive,
further reducing our power for this secondary analysis. We
did, however, note an attenuation of the effect of genotype on
systolic BP when on a low-sodium vs. high-sodium diet
(absolute effect estimate of 2.2 vs. 1.48 mm Hg per Ile allele).
These results suggest potential effect modification or
interaction between dietary salt intake and serum UA effect
on BP. A formal test of interaction did not yield significant
results; however, we must again acknowledge limited power
to detect a statistically significant interaction given the
sample size and modest difference in effect estimate size, as
related to dietary modification of salt intake.
DISCUSSION
In this study, we used the Mendelian randomization principle
to show that decreases in serum UA concentration due to a
missense SNP in the GLUT9 gene are directly associated with
lower level of BP. The strength of the association between
change in serum UA level and systolic BP was significant,
with a 1 mg/dl change in serum UA being associated with an
B3–5 mm Hg change in systolic BP, depending on salt intake.
Considering that the population distribution of serum UA is
much wider than that conferred solely by GLUT9 variability,
the population effect of UA on BP and CV disease outcomes
may be quite substantial.
The full spectrum of mechanisms by which GLUT9 affects
serum UA level continues to be elucidated. It has recently
been shown that GLUT9 is a urate transporter that localizes
to both the apical and basolateral membranes of human renal
proximal tubular cells in vitro; different splice variants affect
trafficking of the transporter and dictate into which
membrane it will be inserted.23 Splice variant 1 localizes to
the basolateral membrane and functions as an efflux
transporter for UA out of the tubular cell, whereas splice
variant 2 is located in the apical membrane and is involved in
the rapid influx of UA into the proximal tubular cell.20,24
Given the location of these two splice variants, it is reasonable
to postulate that GLUT9 may alter serum UA concentration
Table 2 | Observational estimates for uric acid adjusted for age and gender with individual phenotypes compared with
corresponding genotype-based mean phenotype values and additive model point estimates for each Ile allele and
corresponding P-value














Uric acid, mg/dl — — 3.39 (1.46) 3.90 (0.98) 4.29 (1.00) 0.44 (0.06) 3.2 1011
Estimated GFR (ml/min) 4.5 (0.58) 1.38 1014 89.0 (15.8) 95.7 (18.2) 96.0 (18.7) 0.42 (1.12) 0.706
Body mass index (kg/m2) 1.71 (0.14) 1.52 1031 28.4 (5.0) 26.3 (4.3) 26.7 (4.6) 0.24 (0.29) 0.393
Triglycerides 14.2 (1.35) 2.25 1024 71.8 (40.6) 67.3 (42.9) 69.4 (42.9) 2.38 (2.68) 0.347
Glucose 2.47 (0.44) 2.48 108 87.2 (5.7) 85.4 (7.5) 86.6 (10.3) 0.78 (0.84) 0.36
Clinic visit 1 SBP 1.91 (0.48) 7.63 105 115.5 (14.5) 122.2 (14.0) 121.4 (15.0) 0.08 (0.91) 0.378
Clinic visit 1 DBP 1.36 (0.3) 7.71 106 75.7 (7.2) 76.4 (8.9) 76.9 (8.7) 0.52 (0.58) 0.364
High-salt 24-hr SBPa 2.28 (0.51) 8.73 106 112.2 (8.2) 115.3 (9.0) 117.6 (10.8) 2.2 (0.79) 0.006
High-salt 24-h DBPa 1.53 (0.38) 6.41 105 69.4 (5.8) 70.0 (6.2) 70.6 (6.6) 0.42 (0.5) 0.406
Low-salt 24-h SBPa 1.87 (0.49) 1.38 104 110.5 (7.0) 115.1 (8.7) 116.5 (9.0) 1.48 (0.71) 0.038
Low-salt 24-h DBPa 0.88 (0.35) 0.012 69.7 (6.0) 71.3 (6.3) 71.8 (6.0) 0.19 (0.48) 0.689
Salt sensitivity 24-h SBP 0.01 (0.17) 0.954 1.71 (4.3) 0.48 (4.6) 1.05 (5.6) 0.62 (0.49 0.212
Salt sensitivity 24-h DBP 0.04 (0.24) 0.843 0.29 (2.3) 1.22 (3.5) 1.16 (3.8) 0.01 (0.31) 0.986
Abbreviations: CI, confidence interval; DBP, diastolic blood pressure; GFR, glomerular filtration rate; SBP, systolic blood pressure; UA, uric acid.
Estimates of serum UA correlations are based on 1mg/dl change in UA. No significant difference was noted between high- and low-salt diet SBP measures. All blood pressure
measurements are given in mmHg.
aThe 24-h blood pressure measurements were available in a subset of 516 of 868 participants.
Bold indicates P-valueo0.05.
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via regulation of proximal urate reabsorption. The finding
that different SNPs in the GLUT9 gene modify fractional
excretion of UA strengthens this theory.13,24,25 Another
possible mechanism for the effect of GLUT9 on serum UA
concentration is via its role in fructose homeostasis. It has
been well described that increased fructose levels are
associated with increased production of UA.26–29 Given that
UA transport by GLUT9 is facilitated by fructose, it is
plausible to suggest that GLUT9 may also have a role in
calibrating urate concentration in response to fructose.20,30
Although the exact pathway by which serum UA is
associated with higher levels of BP is yet to be established,
previous studies provide several potential mechanisms such
as renal vasoconstriction with microvascular disease,31,32
impaired vascular endothelial function or compliance,33–35
and disturbances in sodium and volume homeostasis.36,37
In an animal model, rats were rendered hyperuricemic by
administration of the uricase inhibitor oxonic acid for 7 weeks
while on a low-salt diet; control animals were maintained on
the same low-salt diet but did not receive oxonic acid. While
still on a low-salt diet, the oxonic acid was then discontinued
for 2 weeks to allow the serum UA levels to return to normal.
The rats were then randomized to a high- or low-salt diet to
assess for salt sensitivity. Only the rats that were previously
hyperuricemic demonstrated an increase in BP on the high-salt
diet (that is, salt sensitivity).37 In agreement with these
findings, we observed suggestive evidence that a high-salt diet
may accentuate the relationship of serum UA on BP. Further
investigation in humans will need to be performed in order
to determine whether elevations in serum UA increase are
associated with salt sensitivity in various populations.
Although the number of subjects studied here is relatively
modest, there are several notable strengths to our study that
should be discussed. Foremost, all participants were on a
standardized prepared diet before obtaining BP measure-
ments, including an equivalent amount of dietary protein
and carbohydrates. As the daily variability in serum UA in a
noncontrolled setting is on the same order as that of the
GLUT9 allele, an uncontrolled dietary setting could sig-
nificantly attenuate findings associated with a modest
increase in serum UA.38 Second, we used 24-h averaged
ambulatory BP measurements on high- and low-salt diets.
In contrast, our regular standardized clinic BP measurements
on a liberal diet did not demonstrate a statistically significant
association between genotype. Moreover, we have repeated
24-h BP measurements in all participants, showing internal
replication. Third, our culturally isolated founder population
is quite homogeneous and not susceptible to population
stratification bias. Fourth, potential gene-by-environment
interactions that are not controlled for in standard popula-
tion-based studies (for example, salt and fructose) are
accounted for in our experimental setting through our
fixed-diet protocol. Fifth, our population is relatively young
and healthy, which may be more sensitive to vascular effects
of serum UA compared with older population with more
vascular disease burden.6,39 Finally, we used direct genotyp-
ing of GLUT9 as opposed to imputation, further minimizing
potential measurement error. In short, limitations related to
potential uncontrolled effect modifiers, interactions, and
measurement error as noted in our liberal diet and single-
visit clinic-based BP measurements have been minimized by
the nature of our selected population and controlled setting.
Not surprisingly, combining large number of heterogeneous
population cohorts in an uncontrolled setting to explore the
association between GLUT9 genotype and BP, where these
limitations could not be mitigated, yielded null results,
comparable to our findings when the participants were on a
liberal diet along with similar single-visit standardized BP
measurement.15,20
In summary, a genetic variant strongly associated with
lower levels of serum UA is also associated with decreases in
BP, when tested in an experimental setting. The evidence
from our Mendelian randomization approach implies that
this association is causal in nature, corroborating all the
previous studies that strongly inferred a causal association
between serum UA and BP. This study also highlights the
potential importance of a controlled setting and homogenous
population when examining secondarily mediated gene
effects (for example, effect of genotype on UA and then
secondarily on BP). These findings add impetus to the
possible benefit of reduced serum UA control in hyperuri-
cemic patients with CV disease risk factors, or established
disease, and suggest that larger clinical trials of serum UA
reduction are well warranted.
MATERIALS AND METHODS
Study sample
The HAPI Heart Study began recruitment in 2003 with the goal of
identifying genes that interact with environmental exposure to alter
risk of CV disease. The study was carried out in an Old Order Amish
community in Lancaster County, Pennsylvania, and the full HAPI
study included 868 individuals aged X20 years who were relatively
healthy. Details of the study aims and recruitment procedures have
been previously described.40 In brief, exclusion criteria included
severe hypertension (BP 4180/105 mm Hg), malignancy, and
kidney, liver, or untreated thyroid disease. The study protocol was
approved by the Institutional Review Board at the University of
Maryland School of Medicine, and informed consent was obtained
from each study participant.
Baseline clinical and serological measurements were obtained
during an initial clinic visit at the Amish Research Clinic in
Strasburg, Pennsylvania. Baseline clinic BP was measured in triplicate
using a standard sphygmomanometer in the sitting position after
5 min of rest, and the average of the three measurements was used for
analysis. Fasting blood samples were also drawn at this time. Serum
UA levels drawn at the screening exam were assayed by Quest
Diagnostics (Baltimore, MD) and measured to the nearest 0.1 mg/dl.
Biochemical measurements relevant to this study include basic
metabolic and lipid panels (Quest Laboratory, Horsham, PA).
Dietary salt intervention. The dietary salt intervention study
began immediately following the clinic visit and was completed in a
subsample of 516 individuals. Study subjects were put on a high-
sodium diet (280 meq per day) for 6 days, which is close to their
customary diet, and then after a 6- to 14-day washout period,
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were put on a low-sodium diet (40 meq per day) for 6 days. The
potassium level was held constant at 140 meq per day during both
diets, as was the daily protein content at 114 g and the total carbo-
hydrate content at 411 g. All meals were prepared in a specially
outfitted kitchen and delivered to the home of the subjects.
Measurement of 24-h ambulatory BP. The 24-h BP measure-
ments were recorded at 30-min intervals by an ambulatory BP
monitor worn by the subjects on the last day of each diet. Salt
sensitivity was expressed on a continuous scale as the absolute
difference between the average 24-h BP during the high- and low-
salt diet. We used the mean of all recorded BP measurements during
each 24-h period as our outcome measure. Specific protocols for the
HAPI Heart study measurements have been published.40
Genotyping of the GLUT9 gene. Participants were genotyped
for the rs16890979 SNP (Val253Ile) using TaqMan SNP Genotyping
Assays (Applied Biosystems, Foster City, CA) according to the
standardized manufacturer’s protocol. Replicate genotyping in 8%
of the samples resulted in a 498% concordance rate.
Analytical approach
Mendelian randomization. The Mendelian randomization
approach exploits the fact that genotype precedes life events and is
therefore not affected by lifestyle factors. As previously reviewed,
Mendelian randomization is an application of instrumental variable
analysis, and with certain assumptions the genotype–phenotype
relation can be used to attain unconfounded estimates of the
relationship between the gene product and outcomes of interest.41
These assumptions include an adequately strong relationship between
genotype and phenotype and the absence of alternate pathways from
genotype to the outcome of interest (for example, pleiotropy,
population stratification, linkage disequilibrium). The first assump-
tion, a strong relation between genotype and phenotype, has been
previously demonstrated for the SNP rs16890979 on the GLUT9 gene
(GLUT9 Val253Ile) and serum UA levels.10–12,16 With regard to
population stratification, our sample population of Old Order Amish
individuals is extremely homogenous with no evidence of population
stratification. We also considered the possibility of pleiotropic effect
of GLUT9 on hexose (that is, glucose/fructose) transport as a
potential source of confounding. However, given that GLUT9 is one
of the principle high-capacity UA transporters and a very low-
capacity fructose transporter (45–60-fold increase in UA transport
capacity compared with glucose/fructose), it seems highly unlikely
that fructose could account for these findings.13,23 Considering the
low capacity for fructose transport, the effect of fructose would have
to be unrealistically strong to mediate a noticeable change in
phenotype. A more plausible scenario is that fructose, by altering the
transport rate of UA by GLUT9,20,30 may account for some of the
noted association between fructose intake and elevations in UA.28,42
Given the missense nature of this highly conserved SNP, predicted
exonic splicing enhancer function (http://compbio.cs.queensu.ca/
F-SNP/), consistent strong linear association of GLUT9 SNPs with
serum UA in numerous cohorts and ethnicities, and demonstrated
role of GLUT9 as a major urate transporter, we are comfortable
assuming that the associations noted in our result section are not
secondary to linkage disequilibrium with another gene or other
violations of the assumptions underlying Mendelian randomization.
Statistical methods
The principle of Mendelian randomization is illustrated by con-
trasting the correlations observed between serum UA levels and BP
risk factors without consideration for the GLUT9 (Val253Ile)
genotype with those obtained between serum UA levels and BP
risk factors using a two-stage approach that uses the genotype–out-
come and genotype–UA regressions. The simple (potentially
confounded) estimates were obtained by regressing serum UA levels
(the independent variable) on each BP risk factor (the dependent
variable) separately, after adjusting for age and gender.
Many of the participants of the HAPI Heart Study are related.
To address the correlations potentially existing in phenotype by
virtue of the fact that subjects are related, we accounted for residual
familial correlations in phenotype using a variance component
regression framework. Specifically, we modeled variation in the trait
as a function of fixed covariates, a polygenic component, and a
normally distributed error component. The polygenic component
was derived from the kinship coefficient matrix, which describes the
relationship of each pair of individuals in the sample. The software
packages SOLAR (Southwest Foundation for Biomedical Research,
San Antonio, TX) and MMAP (University of Maryland School of
Medicine, Baltimore, MD) were used for the analyses.
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